复发性种植失败妇女子宫液中微小RNA表达失调
这项描述性实验室病例对照研究比较了健康经产妇(n=17)与复发性种植失败(RIF,n=34)妇女子宫液中的微小RNA丰度,发现RIF组有61个微小RNA丰度存在差异(34个上调、27个下调),其中hsa-miR-486-5p(FC -20.32;P值=0.004)和hsa-miR-92b-3p(FC -9.72;P值=0.004)经RT-PCR技术验证。
要点
- RIF妇女子宫液微小RNA组成与健康经产妇不同,差异微小RNA与子宫内膜容受性受损及胚胎种植相关。
- RIF组有61个差异丰度微小RNA(34个上调、27个下调),错误发现率<0.05,倍数变化≤-2或≥2。
- hsa-miR-486-5p(FC -20.32;P值=0.004)和hsa-miR-92b-3p(FC -9.72;P值=0.004)在RIF组经RT-PCR验证为下调。
核心结论
- RIF妇女子宫液微小RNA组成与健康经产妇不同,失调微小RNA与子宫内膜容受性受损及胚胎种植相关。
- RIF是当前IVF领域的重大挑战,尚无诊断标志物或有效治疗选择,本研究首次在健康经产妇和RIF妇女子宫液中广泛绘制了容受期微小RNA图谱。
研究设计与样本
- 描述性实验室病例对照研究,比较健康经产妇(n=17)与RIF妇女(n=34)在种植期收集的子宫液微小RNA丰度,RIF定义为三次高质量胚胎IVF周期失败。
- 研究对象招募和子宫液采样在瑞典斯德哥尔摩和爱沙尼亚塔尔图的两所大学诊所进行,受试者用LH试纸监测月经周期,于LH+7-9天用生理盐水冲洗收集子宫液。
- 测序数据处理后,健康经产妇组有15份样本、RIF组有33份样本。
主要发现
- 与健康经产妇相比,RIF组有61个差异丰度子宫液微小RNA(34个上调、27个下调),错误发现率<0.05,倍数变化≤-2或≥2。
- hsa-miR-486-5p(FC -20.32;P值=0.004)和hsa-miR-92b-3p(FC -9.72;P值=0.004)经RT-PCR技术验证成功,在RIF组均为下调。
- 通路分析显示25条在子宫内膜容受性和种植中起关键作用的通路显著富集。
- 差异丰度微小RNA中多个表达于子宫内膜上皮细胞,并已在子宫内膜细胞外囊泡中报道,与子宫内膜容受性和RIF相关。
- 预测靶基因经公开单细胞转录组测序研究评估,在囊胚期胚胎滋养外胚层细胞和子宫内膜中分泌期上皮细胞中均有表达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这是一项描述性研究,研究参与者数量有限。
- 鉴定的差异丰度微小RNA需在更大研究队列中验证。
- 预测的微小RNA靶基因和富集通路需在体外确认和进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is the composition of microRNAs (miRNAs) in uterine fluid (UF) of women with recurrent implantation failure (RIF) different from that of healthy fertile women? SUMMARY ANSWER: The composition of miRNAs in UF of women with RIF is different from that of healthy fertile women and the dysregulated miRNAs are associated with impaired endometrial receptivity and embryo implantation. WHAT IS KNOWN ALREADY: It has previously been demonstrated that the miRNAs secreted from endometrial cells into the UF contribute to the achievement of endometrial receptivity. Endometrial miRNAs are dysregulated in women with RIF. STUDY DESIGN, SIZE, DURATION: In this descriptive laboratory case-control study, miRNA abundancy was compared between UF collected during implantation phase from healthy fertile women (n = 17) and women with RIF (n = 34), which was defined as three failed IVF cycles with high-quality embryos. PARTICIPANTS/MATERIALS, SETTING, METHODS: Recruitment of study subjects and sampling of UF were performed at two university clinics in Stockholm, Sweden and Tartu, Estonia. The study participants monitored their menstrual cycles using an LH test kit. The UF samples were collected on Day LH + 7-9 by flushing with saline. Samples were processed for small RNA sequencing and mapped for miRNAs. The differential abundance of miRNAs in UF was compared between the two groups using differential expression analysis (DESeq2). Further downstream analyses, including miRNA target gene prediction (miRTarBase), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis (g:Profiler) and external validation using relevant published data, were performed on the dysregulated miRNAs. Two miRNAs were technically validated with quantitative real-time PCR (RT-PCR). MAIN RESULTS AND THE ROLE OF CHANCE: After processing of the sequencing data, there were 15 samples in the healthy fertile group and 33 samples in the RIF group. We found 61 differentially abundant UF miRNAs (34 upregulated and 27 downregulated) in RIF compared to healthy women with a false discovery rate of <0.05 and a fold change (FC) of ≤-2 or ≥2. When analyzed with published literature, we found that several of the differentially abundant miRNAs are expressed in endometrial epithelial cells and have been reported in endometrial extracellular vesicles and in association with endometrial receptivity and RIF. Their predicted target genes were further expressed both in the trophectodermal cells of blastocyst-stage embryos and endometrial mid-secretory epithelial cells, as assessed by publicly available single-cell transcriptome-sequencing studies. Pathway analysis further revealed that 25 pathways, having key roles in endometrial receptivity and implantation, were significantly enriched. Hsa-miR-486-5p (FC -20.32; P-value = 0.004) and hsa-miR-92b-3p (FC -9.72; P-value = 0.004) were successfully technically validated with RT-PCR. LARGE SCALE DATA: The data are available in Gene Expression Omnibus (GEO) at https://www.ncbi.nlm.nih.gov/geo/ with GEO accession number: GSE173289. LIMITATIONS, REASONS FOR CAUTION: This is a descriptive study with a limited number of study participants. Moreover, the identified differentially abundant miRNAs should be validated in a larger study cohort, and the predicted miRNA target genes and enriched pathways in RIF need to be confirmed and further explored in vitro. WIDER IMPLICATIONS OF THE FINDINGS: RIF is a major challenge in the current IVF setting with no diagnostic markers nor effective treatment options at hand. For the first time, total miRNAs have been extensively mapped in receptive phase UF of both healthy women with proven fertility and women diagnosed with RIF. Our observations shed further light on the molecular mechanisms behind RIF, with possible implications in future biomarker and clinical treatment studies. STUDY FUNDING/COMPETING INTEREST(S): This work was financially supported by the Swedish Research Council (2017-00932), a joint grant from Region Stockholm and Karolinska Institutet (ALF Medicine 2020, FoUI-954072), Estonian Research Council (PRG1076), Horizon 2020 innovation (ERIN, EU952516) and European Commission and Enterprise Estonia (EU48695). The authors have no competing interests to declare for the current study.
引用
- von Grothusen C, Frisendahl C, Modhukur V, et al. Uterine fluid microRNAs are dysregulated in women with recurrent implantation failure. Hum Reprod. 2022. PMID: 35147192. doi:10.1093/humrep/deac019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。